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The Neuropeptide Y Y5 Receptor Mediates the Blockade of
“Photic-Like” NMDA-Induced Phase Shifts in the Golden Hamster
Paola C. Yannielli and Mary E. Harrington
Department of Psychology and Neuroscience Program, Smith College, Northampton, Massachusetts 01063

Circadian or daily rhythms generated from the mammalian
suprachiasmatic nuclei (SCN) of the hypothalamus can be synchronized by light and nonphotic stimuli. Whereas glutamate
mediates photic information, nonphotic information can in
some cases be mediated by neuropeptide Y (NPY) or serotonin.
NPY or serotonin can reduce the phase-resetting effect of light
or glutamate; however, the mechanisms and level of interaction
of these two kinds of stimuli are unknown. Here we investigate
the effect of NPY on the NMDA-induced phase shift of the
hamster SCN circadian neural activity rhythm by means of
single-unit recording techniques.
NMDA (10–100 M) applied in the early subjective night
induced phase delays in the time of peak firing, whereas doses
in the millimolar range disrupted firing patterns. The NMDAinduced phase delay was blocked by coapplication of NPY

(0.02–200 M). NPY Y1/Y5 and Y5 receptor agonists, but not
the Y2 receptor agonist, blocked the NMDA-induced phase
delay in a similar manner as NPY. The coapplication of a Y5 but
not Y1 receptor antagonist eliminated NPY blockade of NMDAinduced phase delays, suggesting that the Y5 receptor is capable of mediating the inhibitory effect of NPY on photic responses. These results indicate that nonphotic and photic
stimuli may interact at a level at or beyond NMDA receptor
response and indicate that the Y5 receptor is involved in this
interaction. Alteration of Y5 receptor function may therefore be
expected to alter synchronization of circadian rhythms to light.

Circadian or daily rhythms can be synchronized to 24 hr cycles of
the external environment through photic entrainment. Light has
access to the hypothalamic suprachiasmatic nuclei (SCN), which
functions as an endogenous circadian pacemaker in mammals,
through a direct projection from retinal ganglion cells (Ebling,
1996). Light resets circadian rhythm phase during the subjective
night. The daily oscillation in the firing rate of SCN neurons that
can be observed for several ⬃24 hr cycles in vitro (Gillette, 1991)
provides a unique system in which to examine the effect of
resetting stimuli on the circadian clock. Glutamate can reset the
phase of circadian rhythms in spontaneous firing rate in the SCN
in vitro in a manner similar to light (Ding et al., 1994; Shibata et
al., 1994; Biello et al., 1997). Both in vivo and in vitro studies
suggest that NMDA as well as non-NMDA receptors are involved
in mediation of the effect of light on the pacemaker (Colwell and
Menaker, 1992; Ding et al., 1994; Shibata et al., 1994).
A variety of modulatory pathways allow flexibility in the animal’s response to light. The thalamic intergeniculate leaflet projection to the SCN uses neuropeptide Y (NPY) (Harrington,
1997). NPY is able to reduce light-induced phase shifts, and SCN
application of antiserum to NPY enhances photic phase shifts
(Biello, 1995; Weber and Rea, 1997). This effect can be measured
in vitro using glutamate or light (Biello et al., 1997; Yannielli and

Harrington, 2000). However, in vivo experiments showed that
microinjection of NPY into the hamster SCN after a light pulse
decreased the magnitude of the phase advances, without affecting
phase delays (Weber and Rea, 1997). Also, in vitro experiments
showed that, in rats, coapplication of NPY at either circadian
time (CT) 14 or CT 19 actually potentiated the phase-shifting
effect of NMDA (Shibata et al., 1994).
The subtype of NPY receptor underlying NPY modulation of
photic responses has not yet been investigated. The Y1 and Y5
receptors are expressed in rat SCN (Weinberg et al., 1996; Larsen
and Kristensen, 1998), whereas the Y2 receptor appears to mediate the NPY phase-resetting action during the subjective day
(Golombek et al., 1996; Huhman et al., 1996). The blocking effect
of NPY on pituitary adenylate cyclase activating peptide-induced
daytime phase shifts is via the Y1 and/or Y5 receptors (Harrington and Hoque, 1997), whereas in rats, the inhibitory effect of
NPY on serotonergic phase is mediated by Y2 receptors (Prosser,
1998). Y1, Y2, and Y5 receptors have been implicated in the
inhibitory effects of NPY on spontaneous discharge (Liou and
Albers, 1991; van den Pol et al., 1996; Cutler at al., 1998; Gribkoff
et al., 1998), as well as the NPY-induced long-term depression of
glutamate-elicited EPSPs (van den Pol et al., 1996). A selective
agonist as well as antagonist for the NPY Y5 receptor has just
been reported (Cabrele et al., 2000;Youngman et al., 2000).
We report that NPY is able to block NMDA-induced phase
shifts in vitro. We further report that the receptor mediating this
effect is the Y5 receptor, the same receptor implicated in effects
of NPY on food intake (Gerald et al., 1996; Hu et al., 1996) and
seizure activity (Marsh et al., 1999).
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MATERIALS AND METHODS
Animals and tissue preparation. Male golden hamsters (LVG; 40- to
60-d-old; Charles River Laboratories, Wilmington, M A) were housed
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with a 14/10 hr light /dark schedule (lights on at 5:00 A.M.), with food and
water available ad libitum. Z eitgeber time (Z T) was defined as Z T 12
being the projected time of lights off in the animal room. Hamsters were
administered an overdose of halothane anesthesia and decapitated during the subjective day, in most cases between Z T 8 and Z T 10. Hypothalamic slices (500 m) containing the SC N were placed in a gas-fluid
interface slice chamber (Medical Systems brain slice chamber with Haas
top), continuously bathed (1 ml /min) in artificial C SF (AC SF) containing (in mM): 125.2 NaC l, 3.8 KC l, 1.2 K H2PO4, 1.8 C aC l2, 1 MgSO4, 24.8
NaHC O3, and 10 glucose. AC SF, pH 7.4, was supplemented with an
antibiotic (50 mg / l gentamicin) and a f ungicide (2 mg / l amphotericin)
and maintained at 34.5°C. Warm, humidified 95% oxygen –5% carbon
dioxide was continuously provided.
Electrophysiological recordings. Extracellular single-unit activity of SCN
cells was detected with glass micropipette electrodes filled with ACSF,
advanced through the slice using a hydraulic microdrive. Every spontaneously firing cell with a signal distinguishable from noise was recorded. The
signal was fed into an amplifier for additional amplification and filtering and
was continuously monitored by an oscilloscope and audio monitor. Firing
rate was analyzed using data acquisition software and a customized program for calculation of descriptive statistics. A number of experiments in
each condition were recorded “blind” in which the person recording data
had no knowledge of the contents of the microdrop. In the majority of the
cases, only one slice was recorded from each animal, but when a second
slice containing SCN was recordable, the treatment applied was different
from that applied to the first slice of the same animal. A total number of 118
slices were recorded in the present study.
Drugs and treatments. Drugs were applied as a 200 nl microdrop delivered
to the SCN area of the slice at least 4 hr after dissection, on the same day
as slice preparation. When two drops were applied, there was an average of
5 min between drops. Recordings were performed for 6 – 8 hr. All of the
drugs were applied at ZT 14 the same day the slices were prepared. The
recordings started the following day, 2–3 hr before ZT 30 (the projected ZT
6 of the second day in vitro) and lasted until the firing rate returned to
prepeak levels in all cases. The number of slices per treatment (n) is stated
in the corresponding figure or is mentioned in the text.
NMDA (Research Biochemicals, Natick, MA) diluted in fresh ACSF
was applied in concentrations ranging from 1 M to 10 mM. Neuropeptide
Y (rat and human; Bachem Bioscience, Torrance, CA) prepared in ACSF
was applied as 0.002–200 ng in 200 nl (2.34 nM-234 M). The molecular
weight of all of the agonists is very close to that of NPY, so that the higher
concentration applied (200 ng/200 nl) was between 235 and 240 M for all
receptor-specific agonists. Both Y5 agonists, bU8 ([hPP1–17, Ala 31,
Aib 32]NPY) and bV5 ([Ala 31, Aib 32]NPY) (Cabrele et al., 2000), were
generously provided by Dr. A Beck Sickinger (University of Leipzig,
Leipzig, Germany). Y1/ Y5 and Y2 agonists, [Leu 31,Pro 34]N PY and
NPY3–36 respectively, were purchased from Sigma (St. Louis, MO). All of
the NPY receptor agonists were applied the same way as NPY. The Y5
antagonist was generously provided by Dr. S. Dax (RW Johnson Pharmaceutical Research Institute, Spring House, PA). The Y5 antagonist RWJ57926 [␣-(3-pyridylmethyl)-␤-aminotetralin-derived sulfonamide] and the
Y1 antagonist BIBP 3226 (R-N2-(diphenylacetyl)-N-(4-hydroxyphenyl)methyl-argininamide; Research Biochemicals) were prepared in ACSF (2
and 1 M final concentration, respectively), and applied in the bath from
ZT 13.5 to ZT 14.5, alone or in combination with other treatments applied
at ZT 14 as microdrops.
Data anal ysis. Data were initially grouped into 1 hr bins, and an
ANOVA was used to determine whether any bins differed from the
others. If the ANOVA indicated significant differences, data were
smoothed using 1 hr running means with a 15 min lag. The zeitgeber
time of the middle of the 1 hr bin with the highest mean firing rate
after processing by this smoother was taken as the time of peak firing
rate for that slice. Phase shifts of individual slices were measured
relative to the average time of peak firing of control slices. Significant
differences between groups ( p ⬍ 0.05) were determined by ANOVA
followed by Dunnett’s (for all vs control comparison) or Student–
Newman –Keuls (for all pairwise comparison) methods when multiple
comparison procedures were required. Means are reported ⫾SE.

RESULTS
NMDA dose–response curve
NMDA applied at ZT 14 induced a phase delay of the firing rate
activity rhythm in a dose-dependent manner (Fig. 1 A). The time
of peak of control slices (ACSF microdrop at ZT 14), measured

Figure 1. Dose–response curve for the phase-delaying effect of NMDA
applied at ZT 14 on the first day in vitro. The rhythm of spontaneous firing
rate was measured from SCN slices on the second day in vitro, and phase
was measured relative to untreated control slices. A, Shown are the
means ⫾ SE of phase delays (in hours) induced by administration of 1 M
to 10 mM NMDA. The drug was applied in a volume of 200 nl as a
microdrop onto the SCN region. Average time of peak of control slices
(ZT 6.36 ⫾ 0.23 hr) was used to define the phase shift. Number of slices
are shown in brackets. The phase-shifting effect of NMDA was dose
dependent, with all the treatments except 1 M significantly different from
control values ( p ⬍ 0.05; ANOVA followed by Dunnett’s method). B,
Representative individual recordings. Firing rate (in Hertz) of individual
SCN neurons plotted against zeitgeber time of recording during the
second day in vitro. Solid line indicates the running mean smoother.
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Figure 2. Effect of NPY on NMDA-induced phase delays. NPY significantly blocked NMDA-induced phase delays, whereas NPY alone did not
modify the phase of the firing activity rhythm (*p ⬍ 0.05; NMDA alone
vs NMDA plus NPY; ANOVA followed by Student–Newman–Keuls
method). Shown are the means ⫾ SE of phase delays (expressed as hours,
in negative values) induced by 100 M NMDA applied alone or followed
by 200 ng of NPY (234 M). Both drugs were applied in a volume of 200
nl as microdrops onto the SCN region. Control values are shown for
comparison purposes, as well as 200 ng of NPY applied alone. Number of
treated slices is denoted in brackets.

on the second day in vitro, was in the middle of the subjective day
(average ZT, 6.36 ⫾ 0.23 hr) as reported previously. NMDA
induced a significant phase delay at concentrations of 10 and 100
M (2.12 ⫾ 0.16 and 2.55 ⫾ 0.3 hr, respectively), whereas concentrations of and above the millimolar range (1 and 10 mM)
induced a disrupted rhythm pattern, expressed as double peaks
and/or overall diminished firing rate activity. It should be noted
that, although three to four slices were treated with 1 or 10 mM
NMDA, only two of them in each treatment could be included in
the analysis, because the peak was not significant in the ANOVA
of the other recordings. Saturation of the phase-shifting response
to NMDA was achieved at 100 M, which was then chosen as a
working concentration for all of the following experiments, unless
otherwise noted. Representative individual recordings from control and NMDA (100 M)-treated slices are shown in Figure 1 B.

Effect of NPY on NMDA-induced phase delays
As shown in Figure 2, application of 200 ng/200nl NPY (234 M)
5 min after NMDA (100 M) at ZT 14 completely blocked the
phase-delaying effect of NMDA (NMDA average phase shift,
⫺2.55 ⫾ 0.3 hr; NMDA plus NPY average phase shift, ⫺0.35 ⫾
0.1 hr). No significant changes in phase were found after the same
concentration of NPY was applied alone (⫺0.04 ⫾ 0.2 hr). Both
of the clearly phase-shifting concentrations of NMDA (10 and
100 M) were blocked by NPY application (10 M NMDA plus
200 ng/200 nl NPY average phase shift, 0.46 ⫾ 0.05 hr).

Dose–response curves for NPY, Y1/Y5, Y2, and
Y5 agonists
Figure 3 shows the inhibitory effect of several concentrations of NPY
on NMDA-induced phase delays, as well as the effect of the Y1/Y5
([Leu 31,Pro 34]NPY), Y5 [bU8 ([hPP1–17,Ala 31,Aib 32]NPY) and
bV5 ([Ala 31, Aib 32]NPY)] and Y2 (NPY3–36) agonists, applied in
the same way as NPY. NPY blocked the effect of NMDA at
concentrations of 0.02–200 M, whereas at 2 nM (0.002 ng/200 nl) the
blocking effect was no longer evident. Furthermore, the Y1/Y5 and
both Y5 agonists used in this experiment blocked the NMDA-
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Figure 3. Dose–response curves for NPY, Y1/Y5, Y2, and Y5 agonists
blocking effect on NMDA-induced phase delay. Shown are the means ⫾
SE of phase delays expressed in hours. NMDA (100 M) was applied in
all cases at ZT 14, 5 min before the NPY or agonists. The NPY blocking
effect was significant at concentrations as low as 0.02 ng (0.0234 M),
whereas the Y1/Y5 and both Y5 agonists blocked NMDA-induced phase
delays at 0.2 ng (0.235– 0.238 M). The Y2 agonist failed to block the
NMDA phase-delaying effect at 2 ng (2.4 M). None of the agonists
applied alone induced a phase shift of the firing activity rhythm (see
Results). All drugs were applied in a volume of 200 nl, as microdrops onto
the SCN region of the slices. Number of treated slices was two to four per
group.

induced phase delay at concentrations as low as 0.2 M, whereas the
Y2 agonist failed to block the delays at 2 M. No significant changes
in the phase of the firing rate rhythm were found when the agonists
were applied alone at ZT 14 (0.05 ⫾ 0.01 hr for Y1/Y5 agonist; 0.09
hr for Y2 agonist; ⫺0.1 and ⫺0.17 hr for the two Y5 agonists, bV5
and bU8, respectively). The Y1/Y5 and both Y5 agonists paralleled
the effect of NPY even at very low concentrations, suggesting that
the inhibition of photic-induced responses could be achieved
through one or both of these receptors. Figure 4 shows representative recordings of 100 M NMDA, with or without different concentrations of NPY or Y5 agonist.

Effect of Y5 and Y1 antagonists on NPY blockade of
NMDA-induced phase shifts
We decided to test the effect of the selective and potent Y5
antagonist RJW-57926 (McNally et al., 2000; Youngman et al.,
2000) and the Y1 antagonist BIBP 3226 (Rudolf et al., 1994;
Wieland et al., 1995), applied in the bath from ZT 13.5 to ZT
14.5. At ZT 14, NMDA (100 M), alone or in combination with
NPY, was applied as described previously. Figure 5 shows that the
blocking effect of NPY was not affected by 1 hr administration of
the Y1 antagonist (100 M NMDA plus 2.34 M NPY plus 1 M
Y1 antagonist, 0.32 ⫾ 0.13 hr; 100 M NMDA plus 2.34 M NPY,
0.49 ⫾ 0.1 hr) but was eliminated by coapplication of the Y5
antagonist (100 M NMDA plus 2.34 M NPY plus 2 M Y5
antagonist, 3.00 ⫾ 0.15 hr; 100 M NMDA plus 2.34 M NPY,
0.49 ⫾ 0.1). No significant effect of either antagonist applied
alone was found on control time of peak (Y1 antagonist, 0.37 ⫾
0.18 hr; Y5 antagonist, 0.77 ⫾ 0.18) or in NMDA-induced phase
delays (NMDA plus Y1 antagonist, 2.23 ⫾ 0.35 hr; NMDA plus
Y5 antagonist, 2.83 ⫾ 0.19) or NPY applied alone (2.34 M NPY
plus Y1 antagonist, 0.39 hr; 234 M NPY plus Y5 antagonist, 0.01
hr). Figure 6 shows representative individual recordings for the
relevant treatments.
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Figure 4. The phase delay induced by
NMDA (top left) is blocked by NPY at 0.02
ng (top right) and the Y5 agonist (bottom
right) but not by NPY at 0.002 ng (bottom
left). The firing rate of individual neurons
(dots) was plotted against the zeitgeber time
of recording of the second day in vitro. Drugs
were applied as stated in Materials and
Methods. Peak times as indicated by the running mean smoother (line), and treatments
are denoted in each graph showing a representative individual recording.

DISCUSSION
We have demonstrated that NPY can block photic phase shifts via
the Y5 receptor and at some level at or beyond NMDA-receptor
activation in the signal transduction cascade induced by light.
Initially, we characterized NMDA-induced phase shifts in the
early subjective night (ZT 14) in the hamster SCN in vitro.
NMDA induced a phase delay of ⬃3 hr when applied onto the
SCN region. The phase-shifting effect was clearly dose dependent, with maximal phase-delay response at 100 M NMDA. The
phase-shifting effects of NMDA have been shown to be similar to
those of light, in that phase delays are elicited in early subjective
night, phase advances later in the subjective night, with little
phase shifting observed after treatment in the subjective day
(Mintz et al., 1999). It appears that millimolar doses of NMDA
are required for phase-shifting behavioral activity rhythms using
in vivo microinjections of NMDA in hamsters (Mintz et al., 1999).
Doses in the millimolar range in our study induced double peaks
and decreased firing activity in half of the slices. A similar
disrupted pattern was seen after glutamate applications to rat
SCN slices at CT 14 (Shirakawa and Moore, 1994) and might be
similar to responses reported for glutamate applications at ZT 17
in vitro (Ding et al., 1994; Franken et al., 1999).
We demonstrate that NPY blocks the phase-shifting effect of
NMDA at ZT 14. This is similar to our previous results, in which
NPY blocked the phase shifts induced by glutamate or light at ZT
14 and ZT 18 (Biello et al., 1997; Yannielli and Harrington,
2000). It is interesting that novel wheel access, a treatment that
produces phase shifts dependent on NPY (Biello et al., 1994), was
also able to block phase advances to light (Ralph and Mrosovsky,
1992). However, our results are in apparent conflict with several
previously published studies. In rat SCN, coapplication of NPY
potentiates both advance and delay shifts induced by NMDA in
vitro (Shibata et al., 1994). It is unclear why this result is so
different from ours, but it may be significant that these animals
were housed under constant darkness for 24 – 48 hr before experimentation. In a behavioral study, NPY did not alter phase delays

Figure 5. Effect of the Y5 and Y1 antagonists on NPY blockade of
NMDA-induced phase delays. Shown are the means ⫾ SE of phase delays
induced by NMDA (100 M) plus NPY (2 ng), in the presence or absence
of 1 hr perfusion of Y1 antagonist BIBP 3226 (1 M) or Y5 antagonist RWJ
57926 (2 M). The Y5 antagonist significantly reversed the blockade of
NPY on NMDA-induced phase delays, whereas the Y1 antagonist did not
change the blocking effect of NPY on NMDA-induced phase delays. None
of the antagonists interacted with the NMDA effect when applied alone, or
NPY or control peak time values. Significant differences were as follows:
NMDA alone, NMDA plus Y1 antagonist, NMDA plus Y5 antagonist, and
NMDA plus NPY plus Y5 antagonist versus all the other treatments,
including the Y1 and Y5 antagonists applied alone; *p ⬍ 0.05; ANOVA
followed by Student–Newman–Keuls method.
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Figure 6. The NPY-induced block of the
phase delay of NMDA is prevented by bath
application of a Y5 antagonist (bottom right)
but not by the Y1 antagonist (bottom left).
Neither antagonist alone altered the phase delay induced by NMDA (top graphs). The firing
rate of individual neurons (dots) was plotted
against the zeitgeber time of recording of the
second day in vitro. Drugs were applied as
stated in Materials and Methods. Peak times as
indicated by the running mean smoother (line),
and treatments are denoted in each graph
showing a representative individual recording.

to light but did reduce light-induced phase advances (Weber and
Rea, 1997).
There are at least six known subtypes of neuropeptide Y
receptor (for review, see Ingenhoven and Beck-Sickinger, 1999).
The Y2 receptor can be distinguished by its responsiveness to
NPY3–36 (Grandt et al., 1996), whereas [Leu 31,Pro 34]NPY has
often been used as a Y1 receptor agonist (Fuhlendorff et al.,
1990), although it can also bind to the Y5 receptor (Ingenhoven
and Beck-Sickinger, 1999). Two new compounds [bU8 ([hPP1–17,
Ala 31, Aib 32]NPY) and bV5 ([Ala 31, Aib 32]NPY)] bind to the
Y5 receptor with higher affinity than other known NPY receptors
(Cabrele et al., 2000). Also, a new Y5 receptor antagonist (RWJ
57926) has been developed recently and has been shown to bind
selectively and potently to Y5 receptors in vitro, as well as to
inhibit the ingestive behavior in rats (Youngman et al., 2000). Our
work using these compounds indicates that the Y5 receptor mediates the blocking effect of NPY on NMDA-induced phase
shifts. Thus, the receptor by which NPY can induce phase advances during the subjective day [the Y2 receptor (Golombek et
al., 1996; Huhman et al., 1996)] is different from the receptor by
which NPY presumably inhibits photic phase shifts during the
subjective night. The rat SCN shows high levels of expression of
the mRNAs encoding the Y1 and Y5 but not the Y2 or Y4
receptors (Larsen and Kristensen, 1998). The higher levels of
expression of the Y5 versus the Y2 receptor in the SCN might
explain the much lower concentrations of NPY needed to block
NMDA-induced phase shifts (⬃0.02 M) (Fig. 3) versus those
necessary for NPY-induced phase shifts in the subjective day
(⬃20 M) (Golombek et al., 1996).
Our results indicate that NPY acts at some point at or beyond
NMDA receptor response in the light-induced signal transduction cascade. One possibility is that photic and nonphotic signals
could interact via effects on membrane potential. In general,
glutamate is depolarizing (Meijer et al., 1993), whereas NPY is
hyperpolarizing (van den Pol et al., 1996; Hall et al., 1999). NPY
can activate a K ⫹-selective conductance in the SCN, and although the subjective day phase-shifting action of NPY does not

depend on the action of NPY to increase K ⫹ channel conductance (Hall et al., 1999), it remains possible that effects of NPY on
light-induced shifts are mediated via these changes in K ⫹ conductance. Y5 agonists can induce inhibition of firing activity
without affecting the phase of the activity rhythm (Harrington
and Hoque, 1997; Cutler et al., 1998; Gribkoff et al., 1998). These
data suggest that the phase-shifting effect of NPY and the inhibition of light-induced phase shifts by NPY could be mediated by
different mechanisms. It is interesting that serotonin and melatonin also appear to use a different receptor subtype for their
subjective day phase-shifting effects on circadian rhythms than
the subtype mediating inhibitory effects on either photic responses or electrical activity (Rea et al., 1994; Liu et al., 1997;
Pickard and Rea, 1998).
NPY may alter NMDA response by effects on intracellular
calcium levels. NPY induces a long-term depression in glutamatestimulated rises in intracellular calcium levels (van den Pol et al.,
1996). Both the Y1/Y5 and Y2 receptors were implicated in these
effects, which were only seen concomitant with glutamatergic
receptor activation. Serotonergic stimulation is associated with
similar reductions in glutamate-induced calcium responses (Quintero and McMahon, 1999) and also with similar reductions of
light-induced phase shifts (Rea et al., 1994; Pickard and Rea,
1998; Weber et al., 1998). Because activation of the Y5 receptor
also leads to inhibition of cAMP accumulation (Gerald et al.,
1996), cAMP reduction could be a possible mechanism of action.
Recent results have shown that inhibitors of protein kinase A can
block glutamate-induced phase shifts in vitro in rats (Tischkau et
al., 2000), and in our laboratory, we have observed a similar result
using hamsters (our unpublished results). This raises the possibility that NPY could inhibit cAMP accumulation and thus a step
in the light-activated pathway.
NPY may ultimately work by changing gene expression; for
example, altering levels of some recently identified circadian
clock-related genes (for review, see Dunlap, 1999). NPY might
suppress light-induced gene expression and thus might negatively
modulate light input. Preliminary results of our laboratory show

5372 J. Neurosci., July 15, 2001, 21(14):5367–5373

Yannielli and Harrington • NPY Blocks NMDA-Induced Phase Shifts through the Y5 Receptor

that NPY has an inhibitory effect on light-induced per1 and per2
in vitro (McKinley Brewer et al., 2000). During the subjective day,
both NPY and novel wheel access [a stimulus associated with
NPY (Biello et al., 1994; Janik and Mrosovsky, 1994)] can decrease mper1 and mper2 levels in hamster SCN (Maywood et al.,
1999; Fukuhara et al., 2000; Maywood and Hastings, 2000). Because the phase-resetting action of NPY in the subjective day
does not require de novo synthesis of clock proteins (Hall et al.,
1999) and novel wheel access does not alter PER1 protein levels
(Maywood et al., 1999), it is probable that the action of NPY on
levels of per gene mRNA in the subjective day is more closely
related to the action of NPY in the subjective night and does not
play a causal role in the subjective daytime resetting action of
NPY. This is supported by the lack of subjective day resetting
when mPer1 antisense was administered to the suprachiasmatic
nucleus (Akiyama et al., 1999). In summary, the effect of NPY
through its Y5 receptor during the subjective night could be
attributable to many possible mechanisms, including inhibition of
the increased electrical activity elicited by light–glutamate–
NMDA, inhibition of Ca 2⫹ rise, and effects on clock gene
expression.
Under either natural or seminatural conditions, nocturnal rodents, including hamsters, sample light during brief periods to
entrain their internal cycle to the external 24 hr cycle (DeCoursey, 1986; Pratt and Goldman, 1986). NPY appears to play a role
in negatively modulating this fundamental response. NPY is
seasonally regulated in some mammals (Ribelayga et al., 1998)
and thus may alter circadian rhythm entrainment in a seasondependent manner. If verified in humans, the ability of NPY to
modulate the circadian-clock responses to light may be of clinical
importance. Pharmaceuticals that target NPY receptors are under development for use in humans as anti-obesity agents; these
would be expected to also alter photic entrainment of circadian
rhythms. It is important to note that the mechanism by which
NPY blocks photic effects might be different from the mechanism
by which NPY can phase shift the clock during the day. Additional studies should be directed toward understanding the underlying mechanism, as well as the functional relevance of these
effects.

REFERENCES
Akiyama M, Kouzu Y, Takahashi S, Wakamatsu H, Moriya T, Maetani
M, Watanabe S, Tei H, Sakaki Y, Shibata S (1999) Inhibition of lightor glutamate-induced mPer1 expression represses the phase shifts into
the mouse circadian locomotor and suprachiasmatic firing rhythms.
J Neurosci 19:1115–1121.
Biello SM (1995) Enhanced photic phase shifting after treatment with
antiserum to neuropeptide Y. Brain Res 673:25–29.
Biello SM, Janik D, Mrosovsky N (1994) Neuropeptide Y and behaviorally induced phase shifts. Neuroscience 62:273–279.
Biello SM, Golombek D, Harrington ME (1997) Neuropeptide Y and
glutamate block each other’s phase shifts in the suprachiasmatic nucleus
in vitro. Neuroscience 77:1049 –1057.
Cabrele C, Langer M, Bader R, Wieland HA, Doods HN, Zerbe O,
Beck-Sickinger AG (2000) The first selective agonist at the neuropeptide Y Y5-Receptor increases food intake in rats. J Biol Chem
275:36043–36048.
Colwell CS, Menaker M (1992) NMDA as well as non-NMDA receptor
antagonists can prevent the phase-shifting effects of light on the circadian system of the golden hamster. J Biol Rhythms 7:125–136.
Cutler DJ, Piggins HD, Selbie LA, Mason R (1998) Responses to neuropeptide Y in adult hamster suprachiasmatic nucleus neurones in
vitro. Eur J Pharmacol 345:155–162.
DeCoursey PJ (1986) Light-sampling behavior in photoentrainment of a
rodent circadian rhythm. J Comp Physiol [A] 159:161–169.
Ding JM, Chen D, Weber ET, Faiman LE, Rea MA, Gillette MU (1994)
Resetting the biological clock: mediation of nocturnal circadian shifts
by glutamate and nitric oxide. Science 266:1713–1717.
Dunlap JC (1999) Molecular bases for circadian clocks. Cell 96:271–290.

Ebling FJ (1996) The role of glutamate in the photic regulation of the
suprachiasmatic nucleus. Prog Neurobiol 50:109 –132.
Franken P, Cao V, Heller HC, Miller JD (1999) The glutamate induced
phase shift in the SCN slice: a two pulse study. Brain Res 818:34 – 40.
Fuhlendorff J, Gether U, Aakerlund L, Langeland-Johansen N,
Thogersen H, Melberg SG, Olsen UB, Thastrup O, Schwartz TW
(1990) [Leu31, Pro34] neuropeptide Y: a specific Y1 receptor agonist.
Proc Natl Acad Sci USA 87:182–186.
Fukuhara C, McKinley Brewer J, Bittman E, Harrington ME (2000)
Effect of neuropeptide Y on PER1 gene expression in the hamster SCN
in vitro. Soc Res Biol Rhythms Abstr 7:54.
Gerald C, Walker MW, Criscione L, Gustafson EL, Batzl-Hartmann C,
Smith KE, Vaysse P, Durkin MM, Laz TM, Linemeyer DL, Schaffhauser AO, Whitebread S, Hofbauer KG, Taber RI, Branchek TA,
Weinshank RL (1996) A receptor subtype involved in neuropeptideY-induced food intake. Nature 382:168 –171.
Gillette MU (1991) SCN electrophysiology in vitro: rhythmic activity
and endogenous clock properties. In: Suprachiasmatic nucleus: the
mind’s clock (Klein DC, Moore RY, Reppert SM, eds). New York:
Oxford UP.
Golombek DA, Biello SM, Rendon RA, Harrington ME (1996) Neuropeptide phase shifts the circadian clock in vitro via a Y2 receptor.
NeuroReport 7:1315–1319.
Grandt D, Schimiczek M, Rascher W, Feth F, Shively J, Lee TD, Davis
MT, Reeve Jr JR, Michel MC (1996) Neuropeptide Y 3–36 is an
endogenous ligand selective for Y2 receptors. Regul Pept 67:33–37.
Gribkoff VK, Pieschl RL, Wisialowski TA, van den Pol AN, Yocca FD
(1998) Phase shifting of circadian rhythms and depression of neuronal
activity in the rat suprachiasmatic nucleus by neuropeptide Y: mediation by different receptor subtypes. J Neurosci 18:3014 –3022.
Hall AC, Earle-Cruickshanks G, Harrington ME (1999) Role of membrane conductances and protein synthesis in subjective day phase
advances of the hamster circadian clock by neuropeptideY. Eur J Neurosci 11:3424 –3432.
Harrington ME (1997) The ventral lateral geniculate nucleus and the
intergeniculate leaflet: interrelated structures in the visual and circadian systems. Neurosci Biobehav Rev 21:705–727.
Harrington ME, Hoque S (1997) NPY opposes PACAP phase shifts via
receptors different from those involved in NPY phase shifts. NeuroReport 8:2677–2680.
Hu Y, Bloomquist BT, Cornfield LJ, DeCarr LB, Flores-Riveros JR,
Friedman L, Jiang P, Lewis-Higgins L, Sadlowski Y, Schaefer J,
Velazquez N, McCaleb ML (1996) Identification of a novel hypothalamic neuropeptide Y receptor associated with feeding behavior. J Biol
Chem 271:26315–26319.
Huhman KL, Gillespie CF, Marvel CL, Albers HE (1996) Neuropeptide
Y phase shifts circadian rhythms via Y2 -like receptors. NeuroReport
7:1249 –1252.
Ingenhoven N, Beck-Sickinger AG (1999) Molecular characterization of
the ligand-receptor interaction of neuropeptide Y. Curr Med Chem
6:1055–1066.
Janik D, Mrosovsky N (1994) Intergeniculate leaflet lesions and
behaviorally-induced shifts of circadian rhythms. Brain Res
651:174 –182.
Larsen PJ, Kristensen P (1998) Distribution of neuropeptide Y receptor
expression in the rat suprachiasmatic nucleus. Brain Res Mol Brain Res
60:69 –76.
Liou SY, Albers HE (1991) Single unit response of neurons within the
hamster suprachiasmatic nucleus to neuropeptide Y in the hypothalamic slice preparation. Brain Res Bull 27:825– 828.
Liu C, Weaver DR, Jin X, Shearman LP, Pieschl RL, Gribkoff VK,
Reppert SM (1997) Molecular dissection of two distinct actions of
melatonin on the suprachiasmatic circadian clock. Neuron 19:91–102.
Marsh DJ, Baraban SC, Hollopeter G, Palmiter RD (1999) Role of the
Y5 neuropeptide Y receptor in limbic seizures. Proc Natl Acad Sci
USA 96:13518 –13523.
Maywood ES, Hastings MH (2000) The effect of central infusions of
NPY on the expression of clock genes in the suprachiasmatic nuclei of
the mouse. Soc Res Biol Rhythms Abstr 7:32.
Maywood ES, Mrosovsky N, Field MD, Hastings MH (1999) Rapid
down-regulation of mammalian period genes during behavioral resetting of the circadian clock. Proc Natl Acad Sci USA 96:15211–15216.
McKinley Brewer J, Yannielli PC, Harrington ME (2000) Light exposure prior to slice preparation can induce increased PER1 and PER2
levels measured in vitro. Soc Res Biol Rhythms Abstr 7:53.
McNally JJ, Youngman MA, Lovenberg TW, Nepomuceno D, Wilson S,
Dax S (2000) N-Acylated ␣-(3-pyridylmethyl)-␤-aminotetralin antagonists of the human neuropeptide Y Y5 receptor. Bioorg Med Chem
Lett 10:1641–1643.
Meijer JH, Albus H, Weidema F, Ravesloot JH (1993) The effects of
glutamate on membrane potential and discharge rate of suprachiasmatic neurons. Brain Res 603:284 –288.
Mintz EM, Marvel CL, Gillespie CF, Price KM, Albers HE (1999)
Activation of NMDA receptors in the suprachiasmatic nucleus pro-

Yannielli and Harrington • NPY Blocks NMDA-Induced Phase Shifts through the Y5 Receptor

duces light-like phase shifts on the circadian clock in vivo. J Neurosci
19:5124 –5130.
Pickard GE, Rea MA (1998) Serotonergic innervation of the hypothalamic suprachiasmatic nucleus and photic regulation of circadian
rhythms. Biol Cell 89:513–523.
Pratt BL, Goldman BD (1986) Activity rhythms and photoperiodism of
Syrian hamsters in a simulated burrow system. Physiol Behav 36:83– 89.
Prosser RA (1998) Neuropeptide Y blocks serotonergic phase shifts of
the suprachiasmatic circadian clock in vitro. Brain Res 808:31– 41.
Quintero JE, McMahon DG (1999) Serotonin modulates glutamate responses in isolated suprachiasmatic nucleus neurons. J Neurophysiol
82:533–539.
Ralph MR, Mrosovsky N (1992) Behavioral inhibition of circadian responses to light. J Biol Rhythms 7:353–359.
Rea MA, Glass JD, Colwell CS (1994) Serotonin modulates photic
responses in the hamster suprachiasmatic nuclei. J Neurosci
14:3635–3642.
Ribelayga C, Pevet P, Simonneaux V (1998) Possible involvement of
neuropeptide Y in the seasonal control of hydroxyindole-Omethyltransferase activity in the pineal gland of the European hamster
(Cricetus cricetus). Brain Res 801:137–142.
Rudolf K, Eberlein W, Engel W, Wieland HA, Willim KD, Entzeroth M,
Wienen W, Beck-Sickinger AG, Doods HN (1994) The first highly
potent and selective non-peptide neuropeptide Y Y1receptor antagonist: BIBP3226. Eur J Pharmacol 271:R11–R13.
Shibata S, Watanabe A, Hamada T, Ono M, Watanabe S (1994)
N-Methyl-D-aspartate induces phase shifts in circadian rhythm of neuronal activity of rat SCN in vitro. Am J Physiol 267:R360 –R364.
Shirakawa T, Moore RY (1994) Glutamate shifts the phase of the circadian neuronal firing rhythm in the rat suprachiasmatic nucleus in vitro.
Neurosci Lett 178:47–50.

J. Neurosci., July 15, 2001, 21(14):5367–5373 5373

Tischkau SA, Gallman EA, Buchanan GF, Gillette MU (2000) Differential cAMP gating of glutamatergic signaling regulates long-term
changes in the suprachiasmatic circadian clock. J Neurosci
20:7830 –7837.
van den Pol AN, Obrietan K, Cao V, Trombley PQ (1996) Neuropeptide
Y-mediated long term depression of exitatory activity in suprachiasmatic nucleus neurons. J Neurosci 16:5883–5895.
Weber ET, Rea MA (1997) Neuropeptide Y blocks light-induced phase
advances but not delays of the circadian activity rhythm in hamsters.
Neurosci Lett 231:159 –162.
Weber ET, Gannon RL, Rea MA (1998) Local administration of serotonin agonists blocks light-induced phase advances of the circadian
activity rhythm in the hamster. J Biol Rhythms 13:209 –218.
Weinberg DH, Sirinathsinghji DJ, Tan CP, Shiao LL, Morin N, Rigby
MR, Heavens RH, Rapoport DR, Bayne ML, Cascieri MA, Strader
CD, Linemeyer DL, MacNeil DJ (1996) Cloning and expression of a
novel neuropeptide Y receptor. J Biol Chem 271:16435–16438.
Wieland HA, Willim KD, Entzeroth M, Wienen W, Rudolf K, Eberlein
W, Engel W, Doods HN (1995) Subtype selectivity and antagonistic
profile of the nonpeptide Y1 receptor antagonist BIBP 3226. J Pharmacol Exp Ther 275:143–149.
Yannielli PC, Harrington ME (2000) Neuropeptide Y applied in vitro
can block the phase shifts induced by light in vivo. NeuroReport
11:1587–1591.
Youngman MA, McNally JJ, Lovenberg TW, Reitz AB, Willard NM,
Nepomuceno DH, Wilson SJ, Crooke JJ, Rosenthal D, Vaidya AH,
Dax SL (2000) ␣ -Substituted N-(sulfonamido)alkyl-␤-aminotetralins:
potent and selective neuropeptide Y Y5 receptor antagonists. J Med
Chem 43:346 –350.

